Withdrawn medicines included in the essential medicines lists of 136 countries

Onella Charles1, Igho Onakpoya2, Simran Benipal1, Hannah Woods1, Anjli Bali1, Jeffrey K. Aronson2, Carl Heneghan2, Nav Persaud1,3*

1 MAP Centre for Urban Health Solutions, St. Michael’s Hospital, Toronto, Canada, 2 Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom, 3 Department of Family and Community Medicine, St. Michael’s Hospital, Toronto, Ontario

* nav.persaud@utoronto.ca

Abstract

Background

Essential medicines lists and related policies are intended to meet the priority health needs of populations and their implementation is associated with more appropriate use of medicines. The World Health Organization (WHO) recommends that countries carefully select the medicines to be included in their national essential medicines lists. Lists that are used to prioritize access to important treatments should not include medicines that have been withdrawn elsewhere because of an unfavourable benefit-to-harm balance; however, countries still list and use medicines that have been withdrawn worldwide. The objective of this study was to determine whether the national essential medicines lists of 137 countries include medicines that have been withdrawn in other countries.

Methods and findings

We performed an audit of national essential medicines lists for medicines that had been withdrawn. Medicines withdrawn from worldwide markets between 1953 and 2014 were identified using a systematic review of published literature and regulatory documents. The reviewers used sources including the WHO’s database of drugs, PubMed, and the websites of regulatory agencies to obtain information regarding adverse effects associated with the medicines, the year of first withdrawal, markets of withdrawal, and the level of evidence supporting each withdrawal. We recorded the number of countries with a withdrawn medicine included in their national medicines list, the number of withdrawn medicines included in each nation’s list, and the number of national essential medicines including each withdrawn medicine. 97 medicines were withdrawn in at least one country but still included in one more national essential medicines list. Of 137 countries with a national essential medicines list, 136 lists included at least one withdrawn medicine, with 54% of the lists containing 5 or fewer withdrawn medicines, and 27% including 10 or more withdrawn medicines. 11 medicines were withdrawn worldwide but still included on at least one national essential medicines list. Countries with longer essential medicines lists had more withdrawn medicines included in their lists.
Conclusions

This study found that withdrawn medicines are included in all but one national essential medicines list, representing a need for more stringent processes for selecting and removing medicines on these lists. Countries may wish to apply special scrutiny to medicines withdrawn in other nations when selecting medicines to include on their lists.

Introduction

Essential medicines lists and related policies are intended to meet the priority health needs of populations [1]. They can promote health and patient safety and their implementation, especially in low-income countries, is associated with more appropriate use of medicines [2–4]. The World Health Organization (WHO) recommends that countries carefully select the medicines to be included in their national essential medicines lists [5]. Essential medicines lists contain medicines that are publicly paid for and medicines may not be on essential medicines lists but may still be available publicly. Lists that are used to prioritize access to important treatments should not include medicines that have been withdrawn elsewhere because of an unfavourable benefit-to-harm balance.

Delays in the removal of harmful medicines from the market can lead to substantial morbidity and mortality [6]. For example, cyclo-oxygenase 2 (COX2) inhibitors (coxibs) caused approximately 30 000 excess deaths in the United States before they were withdrawn [7, 8]. Sertindole, used in the treatment of schizophrenia, was available in 13 countries until it was withdrawn because of an association with sudden cardiac death [9]. Yet these medicines are still available and used in some countries. The purpose of this study was to determine whether national essential medicines lists include medicines that have been withdrawn in at least one other country. This study includes the 137 countries that have publicly posted essential medicines lists. Countries may want to consider removing these withdrawn medicines from their essential medicines lists.

Methods

Search Strategy

We identified withdrawn medicines from a systematic review of published literature and regulatory documents, which identified medicines that were withdrawn from markets around the world between 1953 and 2014 because of adverse drug reactions [10]. The reviewers obtained information regarding the year of first withdrawal, the markets of withdrawal, and the time of the first reported adverse drug reactions, using the following sources: the WHO’s database of drugs, Google Scholar, PubMed, textbooks, and the websites of regulatory agencies. The systematic review assessed the evidence supporting each medicine’s withdrawal by documenting the highest level of evidence available before the medicine’s year of first withdrawal. The evidence was classified using the five levels of the Oxford Centre for Evidence Based Medicine: 1 –systematic review; 2 –randomized clinical trials; 3 –non-randomized, cohort, or follow up studies; 4 –case series; 5 –mechanism based reasoning, where lower numbers indicate better evidence [10, 11] [see S2 Table].

We defined a medicine as “a product that is intended to be taken by or administered to a person or animal for one or more of the following reasons: (i) as a placebo; (ii) to prevent a disease; (iii) to make a diagnosis; (iv) to test for the possibility of an adverse effect; (v) to modify a
physiological, biochemical, or anatomical function or abnormality; (vi) to replace a missing factor; (vii) to ameliorate a symptom; (viii) to treat a disease; and/or (ix) to induce anesthesia.”

All medicines’ names were recorded as they were listed in the database of national essential medicines lists. We treated bases and their salts as the same medicinal product (e.g. bendazac lysine and bendazac).

In order to determine whether withdrawn medicines were included in a national essential medicines list, we searched a database of the most recent national essential medicines lists derived from lists compiled by the World Health Organization.

Inclusion/exclusion criteria
We included all withdrawn medicines that met one of the following criteria:

• a medicine whose importation, sale, marketing, use, manufacturing, and/or distribution has been prohibited or banned in at least one national market because of adverse effects or reactions or lack of proven efficacy;

• a medicine whose marketing authorization has been suspended, removed, withdrawn, and/or cancelled in at least one market because of adverse effects or reactions or lack of proven efficacy;

• a medicine whose registration has been cancelled, suspended, or refused in at least one national market because of adverse effects or reactions or lack of proven efficacy;

• a medicine whose approval has been withdrawn in at least one national market because of adverse effects or reactions or lack of proven efficacy;

• a medicine whose suspension of market authorization or market withdrawal has been required by a National Regulatory Health Agency because of adverse effects or reactions.

We use the term “withdrawn” to refer to both medicines that have been withdrawn by a regulator after marketing and those that were not approved for marketing because of adverse effects. In the latter case, a regulator has decided that the medicine should not be made available even though the medicine may be available in other markets.

Additionally, all withdrawn medicines that met one of the following criteria were excluded:

• any medicine that was temporarily removed, withdrawn, or suspended, but later reintroduced into the market of withdrawal;

• any medicine whose use is withdrawn, prohibited, or banned only for certain indications (e.g. contraindicated for paediatric use) or any medicine whose use is strictly regulated or controlled (e.g. included in a controlled substance schedule);

• any medicine whose use is withdrawn, prohibited, or banned only for specific formulations, preparations, or routes of administration (e.g. topical or intravenous);

• any medicine that has been withdrawn in one or more national markets but is on the WHO’s Essential Medicines List (EML).

Withdrawal details
We obtained the years and markets of withdrawal for each medicine by searching the WHO’s consolidated list of products whose consumption or sale have been banned, withdrawn,
severely restricted, or not approved by governments (12th and 14th editions) [14, 15]. When medicines were not found in the WHO consolidated list, the following alternative sources were searched: the Drug Bank database [16], websites of national regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency, and Medline. Only markets that withdrew, banned, or prohibited a medicine in all preparations and formulations were considered markets of complete withdrawal.

We obtained information about the adverse drug reactions associated with each medicine from the 2016 systematic review [10]. We also searched Medline for additional information about the adverse drug reactions. The type of evidence supporting each withdrawal was classified using the Oxford Centre for Evidence Based Medicine criteria [10, 11].

Classification of withdrawal

We classified the reason for withdrawal of each medicine into one of three categories: harm that is unique to the medicine, harm that is general to the chemical subgroup, or lack of proven efficacy [see S2 Table]. This was done by comparing each withdrawn medicine to other medicines in the same therapeutic subgroup. The therapeutic subgroup of each medicine was identified using level 2 of the medicine’s Anatomical Therapeutic Classification (ATC) code [17]. If the adverse effects of the withdrawn medicine were not common among other medicines of the same subgroup, the harm was considered “unique to the medicine” whereas, if similar adverse effects were identified across multiple drugs of the same subgroup, the harm was considered “general to the chemical subgroup”. One reviewer (OC) extracted the data for all 97 withdrawn medicines, and a second reviewer (SB) independently extracted the data for five randomly selected medicines to verify the accuracy of data extraction. Two reviewers (OC and SB) independently assessed the reasons for withdrawal and a third (NP) arbitrated when there were disagreements.

Patient and public involvement

This audit of essential medicines lists for withdrawn medicines did not directly involve patients or members of the public.

Data sharing

The datasets analyzed during the current study are available at essentialmeds.org. To access the datasets, click on Global Essential Medicines, and then click “go to website.”

Results

Of the previously identified 462 withdrawn medicines, 195 (42%) were listed on at least one national essential medicines list. After exclusions, we included 97 (21%) withdrawn medicines that were included on at least one national essential medicines list (Fig 1). Eight medicines (buprenorphine, codeine, levamisole, phenobarbital, podophyllum resin, two salts of erythromycin and rotavirus vaccine) were excluded because they were included in the World Health Organization’s model essential medicines list and would thus be included in many national essential medicines lists based on guidance from the World Health Organization. We included rofecoxib as regulators issues statements about safety concerns around the time it was voluntarily withdrawn by the manufacturer.[18, 19] Characteristics of the 137 countries with a national essential medicines list are presented in S1 Table.

Of the 97 withdrawn medicines, the two most common therapeutic subgroups were “psychoanaleptics” (ATC section N06, including antidepressants and psychostimulants; 10%) and
"antiinflammatory and antirheumatic products" (ATC section M01; 10%) [see S2 Table]. Of the 97 withdrawn medicines, 73% were withdrawn because of harm unique to the medicine, 25% were withdrawn because of harm general to the chemical subgroup, and 2% were withdrawn because of lack of proven efficacy.

Most of the medicines (63%) were withdrawn on the basis of case reports (Level 4 evidence). Of the 137 national essential medicines list, 136 included at least one withdrawn medicine (Fig 2).
The number of withdrawn medicines in the 136 countries’ lists ranged from 1 to 44 (median 5, IQR 3–10); 0.4% to 4.5% of the medicines on country lists were withdrawn (Fig 3). Of these 136 countries, 54% listed up to 5 withdrawn medicines, while more than a quarter (27%) listed between 10 and 44. Countries with longer essential medicines lists tended to include more withdrawn medicines (Fig 4).

The number of countries that included each withdrawn medicine on their essential medicines lists ranged from 1 to 121 (median 4, IQR 2–12). Of the 97 withdrawn medicines included, 22 were on one country’s essential medicines list, 42 were listed on 2 to 10 national essential medicines lists, and the remaining 32 were listed on up to 121 national medicines lists.

Of the 97 withdrawn medicines, 11 were withdrawn worldwide (Table 1), 50 were withdrawn only in one or more European countries, 6 were withdrawn only in one or more North American countries, 11 were withdrawn in both Europe and North America, and 19 were withdrawn only in other countries. Seventeen medicines were withdrawn in at least one African country, 45 in at least one Asian country, 9 in at least one Australasian country, and 26 in at least one Central American or South American country.

Of the 97 withdrawn medicines, 72 were withdrawn in at least one European country. The number of essential medicines lists that included these 71 medicines ranged from 1 to 121 (median 3, IQR 2–11). Twenty-eight (29%) of the 97 medicines were withdrawn in North America and were included in 1 to 39 essential medicines lists (median 3, IQR 1–4). Eleven medicines were withdrawn worldwide and were included in 1 to 39 essential medicines lists (median 2, IQR 1–3) (Table 1).

Discussion

Although essential medicines are intended to meet priority health needs, all national essential medicines lists bar one contain a medicine that has been withdrawn elsewhere. Over half of
the countries include no more than five withdrawn medicines, but more than a quarter (27%) list 10 or more. Most of the 97 withdrawn medicines were listed in more than one list and most were withdrawn on the basis of case reports suggesting harms; 11 were withdrawn worldwide. Some were withdrawn because of serious adverse reactions with an increased risk of death: thioridazine is included in 39 lists, although it was withdrawn worldwide in 2005, cisapride is included in 9 lists, and rosiglitazone is included in 18 lists. As national essential medicines lists are updated, withdrawn medicines should be flagged for removal.

The number of withdrawn medicines correlates with the total number of medicines on EMLs, with those listing a higher total of medicines listing more withdrawn medicines. This could be because countries that list a larger number of medicines have a less stringent process for developing and maintaining their EMLs, and so withdrawn medicines are left on their lists.

In this study we focused on the inclusion of withdrawn medicines in essential medicines lists, while previous studies have shown that some medicines that have been withdrawn in one country continue to be available in other countries. A systematic review showed that of 95
medicines withdrawn in at least one country because of associated deaths, 16 were still marketed elsewhere [6]. A 2015 study showed that 27 medicines withdrawn internationally were still being used in some countries, while a 2012 commentary reported that only 19% of medicines withdrawn in at least one country were also withdrawn internationally [20, 21].

We have comprehensively searched national essential medicines lists for medicines that have been withdrawn elsewhere. There are some limitations to this study. We may have missed some withdrawn medicines, as the 2016 systematic review did not include information from certain African countries, such as Somalia, owing to armed conflict. The systematic review only included medications withdrawn between 1953 and 2014; more medications may have been withdrawn since and may be listed on national essential medicines lists [10]. Companies may voluntarily withdraw medicines when it is clear that the regulator will act to remove them from the market, and these medicines may not appear in the literature we consulted. The database of national essential medicines lists was based on information provided to the World Health Organization, which may have been out of date or abstracted incorrectly [13].

Even when a medicine is withdrawn in a specific country, there may be a delay before these changes are implemented in clinical practice and the medicine is no longer used. Additionally, it is not clear how withdrawn medicines are being used in the countries that include them in

---

**Fig 4. Number of withdrawn medicines included on national essential medicines lists according to the number of medicines on each essential medicines lists, country sub-region, and national GDP.** The area of the circle represents national GDP (larger circle, larger national GDP), and the color of the circle represents sub-region.

https://doi.org/10.1371/journal.pone.0225429.g004
Table 1. Medicines withdrawn worldwide that are included in one or more national essential medicines lists.

| Withdrawn medicine | Year of withdrawal | Safety concern | National essential medicines lists including withdrawn medicine and year of most recent list update |
|--------------------|--------------------|----------------|--------------------------------------------------------------------------------------------------|
| Astemizole         | 1999               | Cardiotoxicity, drug-drug interactions | Slovakia—2012, Syrian Arab Republic—2008 |
| Chlormezanone      | 1996               | Toxic epidermal necrosis | Côte d'Ivoire—2014, Ethiopia—2014, Syrian Arab Republic—2008 |
| Drotrecogin alfa   | 2011               | Failure to show benefits | Mexico—2011, Oman—2009, Syrian Arab Republic—2008, The former Yugoslav Republic of Macedonia—2008 |
| Fenfluramine        | 1997               | Cardiovascular, pulmonary | Lesotho—2005 |
| Laropiprant        | 2013               | Increased serious, but nonfatal adverse effects | Portugal—2011 |
| Nebucumab          | 1993               | Accelerated deaths | Bahrain—2015, Cote d'Ivoire—2014, Ethiopia—2014, Syrian Arab Republic—2008 |
| Nikethamide        | 1988               | Neurotoxicity | China—2012, Cuba—2012, Myanmar—2010 |
| Rofecoxib          | 2004               | Increased risk of heart attacks | Syrian Arab Republic—2008 |
| Suprofen           | 1986               | Nephrotoxicity | Ethiopia—2014 |
| Terodiline         | 1992               | Cardiac arrhythmias | Iraq—2010, Slovenia—2012, Bangladesh—2011, Botswana—2012, Cote d'Ivoire—2014, Ethiopia—2014, Estonia—2014, Fiji—2014, Georgia—2014, Greenland—2014, India—2014, Indonesia—2014, Ireland—2014, Israel—2014, Japan—2014, Jordan—2014, Kenya—2014, Kyrgyz Republic—2014, Laos—2014, Liechtenstein—2014, Lithuania—2014, Macao—2014, Macedonia—2014, Malaysia—2014, Maldives—2014, Marshall Islands—2014, Mauritania—2014, Mauritius—2014, Mexico—2014, Moldova—2014, Morocco—2014, Nepal—2014, Netherlands—2014, New Zealand—2014, Nicaragua—2014, Oman—2014, Pakistan—2014, Panama—2014, Paraguay—2014, Peru—2014, Philippines—2014, Poland—2014, Portugal—2014, Qatar—2014, Republic of Korea—2014, Romania—2014, Russian Federation—2014, Saint Kitts and Nevis—2014, Sao Tome and Principe—2014, Saudi Arabia—2014, Senegal—2014, Sierra Leone—2014, Singapore—2014, Sri Lanka—2014, Sweden—2014, Switzerland—2014, Tajikistan—2014, Tanzania—2014, Thailand—2014, Turkey—2014, United Arab Emirates—2014, United Kingdom—2014, United States—2014, Uruguay—2014, Uzbekistan—2014, Vietnam—2014, Yemen—2014, Zambia—2014, Zimbabwe—2014 |
| Thioridazine       | 2005               | Cardiac arrhythmias, QT prolongation | Antigua and Barbuda—2007, Barbados—2011, Belize—2008, Bolivia—2011, Botswana—2012, Bulgaria—2011, Chile—2010, Colombia—2011, Cuba—2012, Dominica—2007, Eritrea—2010, Ethiopia—2014, Grenada—2007, Guyana—2010, Iran (Islamic Republic)—2014, Kiribati—2009, Lesotho—2005, Maldives—2009, Marshall Islands—2007, Montenegro—2011, Mozambique—2017, Namibia—2016, Nepal—2016, Nicaragua—2011, Oman—2009, Peru—2012, Russian Federation—2014, Saint Kitts and Nevis—2007, Saint Lucia—2007, Saint Vincent and the Grenadines—2010, Serbia—2010, Thailand—2013, The former Yugoslav Republic of Macedonia—2008, Tonga—2007, Trinidad and Tobago—2010, United Republic of Tanzania—2017, Uruguay—2011, Venezuela (Bolivarian Republic)—2004, Viet Nam—2008 |

https://doi.org/10.1371/journal.pone.0225429.t001
their essential medicines lists. A country’s EML may not be used in practice and so listed medicines may not be used. [22] The fact that a medicine has been withdrawn does not necessarily mean that it should not be listed in essential medicines lists; this may be especially so when the evidence supporting withdrawal is poor or limited. For example, neomycin, which was banned in Bangladesh in 1982, is still included on 105 essential medicines lists and may still be a reasonable medicine to include on these lists. On the other hand, medicines listed by majority of countries may still be inappropriately included on essential medicines lists because of their associations with harm. For example, the nonsteroidal anti-inflammatory drug diclofenac, which was refused for registration in the Philippines and Norway in 1983 and 1987 respectively (and later approved for use for the first time in Norway in 2006 [23]), is listed by almost 90% of countries. However, a 2014 study recommended that diclofenac be removed from all essential medicines lists and have its marketing authorization internationally revoked given its similar cardiovascular risks to rofecoxib, a medicine that has been withdrawn worldwide [24]. Medicines may also be rightly withdrawn based on what is considered poor evidence (level 4 for example), if the safety concern is serious enough. Where safety concerns are serious, it would be unethical to seek to establish higher levels of evidence. We excluded some medicines with potentially fatal adverse effects, such as fenoterol (included in 31 lists), because its approval was revoked for only one indication and its use is permitted for mild and moderate asthma.

The presence of withdrawn medicines in national essential medicines lists represents an opportunity for improvement. When selecting medicines for an essential medicines list and when updating existing lists, countries may want to apply special scrutiny to medicines that have been withdrawn in other countries. Countries with longer essential medicines lists may want to adopt more stringent processes that would exclude medicines withdrawn elsewhere. We acknowledge that in low resource settings this activity may have to compete with more pressing demands on the country’s essential medicines program. Universal guidelines for withdrawing medicines may improve communication between international regulatory agencies and reduce the current confusion caused by conflicting regulatory decisions in different countries, although there may be good reasons for different decisions made by different countries. This communication would be aided by a single public site where countries could record their regulatory withdrawal decisions with reasons for their actions. Countries could now prioritize the 11 medicines that have been withdrawn worldwide for removal from their essential medicines lists. The WHO could provide explicit guidance to countries updating their national essential medicines lists to review its list of withdrawn medicines [14, 15]. Future studies could estimate the use and health effects of withdrawn medicines in the countries that list them and compare this to the resources needed to review lists, especially in low- and middle-income countries. This could help determine which withdrawn medicines should no longer be included on any national essential medicines list.

**Supporting information**

S1 Table. Characteristics of the 137 countries with a national essential medicines list.
(DOCX)

S2 Table. Characteristics of medicines withdrawn in at least one country that are included in one or more national essential medicines lists.
(DOCX)

S1 File. STROBE Checklist.
(DOCX)
Author Contributions

Conceptualization: Igho Onakpoya, Nav Persaud.

Data curation: Onella Charles, Simran Benipal, Hannah Woods, Anjli Bali.

Formal analysis: Onella Charles, Simran Benipal, Nav Persaud.

Investigation: Onella Charles, Simran Benipal, Hannah Woods, Anjli Bali, Jeffrey K. Aronson, Carl Heneghan, Nav Persaud.

Methodology: Onella Charles, Igho Onakpoya, Simran Benipal, Jeffrey K. Aronson, Carl Heneghan, Nav Persaud.

Resources: Onella Charles, Igho Onakpoya, Simran Benipal, Hannah Woods, Anjli Bali, Jeffrey K. Aronson, Carl Heneghan, Nav Persaud.

Validation: Igho Onakpoya, Hannah Woods, Anjli Bali, Jeffrey K. Aronson, Carl Heneghan, Nav Persaud.

Visualization: Onella Charles, Simran Benipal.

Writing – original draft: Onella Charles, Nav Persaud.

Writing – review & editing: Onella Charles, Igho Onakpoya, Simran Benipal, Hannah Woods, Anjli Bali, Jeffrey K. Aronson, Carl Heneghan, Nav Persaud.

References

1. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Jongeheer CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet (London, England). 2017; 389(10067):403–76. Epub 2016/11/12. https://doi.org/10.1016/s0140-6736(16)31599-9 PMID: 27832874.

2. Persaud N, Ahmad H. Canadian list of essential medications: Potential and uncertainties. Canadian family physician Medecin de famille canadien. 2017; 63(4):266–8. Epub 2017/04/14. PMID: 28404694.

3. Holloway KA, Henry D. WHO Essential Medicines Policies and Use in Developing and Transitional Countries: An Analysis of Reported Policy Implementation and Medicines Use Surveys. PLOS Medicine. 2014; 11(9):e1001724. https://doi.org/10.1371/journal.pmed.1001724 PMID: 25228527.

4. Holloway KA, Rosella L, Henry D. The Impact of WHO Essential Medicines Policies on Inappropriate Use of Antibiotics. PLOS ONE. 2016; 11(3):e0152020. https://doi.org/10.1371/journal.pone.0152020 PMID: 27002977.

5. World Health Organization. Essential medicines selection—national medicines list/formulary/standard treatment guidelines: World Health Organization; c2018 [cited 2018 July 20]. http://www.who.int/selection_medicines/country_lists/en/#B.

6. Onakpoya IJ, Heneghan CJ, Aronson JK. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. BMC Med. 2015; 13:26. Epub 2015/02/06. https://doi.org/10.1186/s12916-014-0262-7 PMID: 25651859.

7. Topol EJ. Failing the public health—rofecoxib, Merck, and the FDA. The New England journal of medicine. 2004; 351(17):1707–9. Epub 2004/10/08. https://doi.org/10.1056/NEJM048286 PMID: 15470193.

8. Valthianathan R, Hockey PM, Moore TJ, Bates DW. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. Drug safety. 2009; 32(4):335–43. Epub 2009/04/25. https://doi.org/10.2165/00002018-200932040-00007 PMID: 19388724.

9. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999; 281(18):1728–34. Epub 1999/05/18. https://doi.org/10.1001/jama.281.18.1728 PMID: 10328074.

10. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC medicine. 2016; 14:10-. https://doi.org/10.1186/s12916-016-0553-2 PMID: 26843061.

11. Centre for Evidence-Based Medicine. OCEBM Levels of Evidence Centre for Evidence-Based Medicine, University of Oxford2016 [updated May 1, 2016; cited 2018 November 28]. https://www.cebm.net/2016/05/ocebmlvelsofevidence/.
12. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug safety. 2005; 28(10):851–70. Epub 2005/09/27. https://doi.org/10.2165/00002018-200528100-00003 PMID: 16180936.

13. Persaud N, Jiang M, Shaikh R, Ball A, Oronsaye E, Woods H, et al. Similarities and Differences in Essential Medicines Lists of 137 Countries: a quantitative analysis. Bulletin of the World Health Organization 2019; Accepted for publication.

14. Nations United. Consolidated List of Products—Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments. Pharmaceuticals—Economic & Social Affairs. 2005;(12th):1–598.

15. Nations United. Consolidated List of Products—Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments. Pharmaceuticals—Economic & Social Affairs. 2008;(14).

16. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic acids research. 2018; 46(D1):D1074–d82. Epub 2017/11/11. https://doi.org/10.1093/nar/gkx1037 PMID: 29126136

17. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2018: Norwegian Institute of Public Health; 2018 [updated December 20, 2017; cited 2018 May 14]. https://www.whocc.no/atc_ddd_index/.

18. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (London, England). 2004; 364(9450):2021–9. Epub 2004/12/08. https://doi.org/10.1016/s0140-6736(04)17514-4 PMID: 15582059.

19. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from the market. CMAJ. 2004; 171(9):1027–8. https://doi.org/10.1503/cmaj.1041606 PMID: 15505253

20. Lee KH, Kim GJ, Kim JH. Correlation between Drug Market Withdrawals and Socioeconomic, Health, and Welfare Indicators Worldwide. Journal of Korean medical science. 2015; 30(11):1567–76. Epub 2015/11/06. https://doi.org/10.3346/jkms.2015.30.11.1567 PMID: 26538999

21. Ninan B, Wertheimer Al. Withdrawing Drugs in the U.S. Versus Other Countries. Innovations in Pharmacy. 2012; 3(3):1–13.

22. Mahnic-Ka knjo M, Jelicic-Kadic A, Utrobicic A, Chan K, Bero L, Marusic A. Essential medicines availability is still suboptimal in many countries: a scoping review. Journal of clinical epidemiology. 2018; 98:41–52. Epub 2018/02/17. https://doi.org/10.1016/j.jclinepi.2018.02.006 PMID: 29452222.

23. Den Norske Legeforening. Diclofenac 2006 [cited 2019]. https://legeforeningen.no/Fagmed/Norsk-reumatologisk-forening/Pasientinformasjon/pasientinformasjon-om-legemidler/diclofenac-tbl/.

24. McGettigan P, Henry D. Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries. PLOS Medicine. 2013; 10(2):e1001388. https://doi.org/10.1371/journal.pmed.1001388 PMID: 23424288